MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-09-2022
Epizyme ROCE Ratio 2011-2025 | EPZM
Annual ROCE Ratio Epizyme
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 1150.39 | -52.4 | -45.4 | -53.9 | -51.7 | -48.45 | -66.46 | -30.22 | -2.44 | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1150.39 | -66.46 | 88.83 |
Quarterly ROCE Ratio Epizyme
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -164.0 | -728.0 | -1145.03 | -1378.1 | -555.43 | -589.04 | -201.4 | -146.43 | -121.91 | -105.67 | -87.73 | -71.91 | -53.5 | -46.56 | -51.65 | -49.32 | -54.98 | -60.42 | -60.04 | -59.15 | -58.14 | -59.86 | -56.0 | -57.99 | -55.44 | -50.99 | -52.31 | -53.44 | -78.19 | -74.46 | -73.14 | -66.24 | -34.35 | -9.35 | -6.36 | -0.14 | -3.0 | -9.71 | -9.07 | -16.39 | -9.22 | -18.09 | -9.4 | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -0.14 | -1378.1 | -153.29 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ARCA biopharma
ABIO
|
-23.06 | - | 1052.0 % | $ 415 M |  USA |
 |
Alpine Immune Sciences
ALPN
|
-32.41 | - | - | $ 2.17 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-73.67 | $ 4.76 | 1.82 % | $ 790 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
-91.24 | $ 3.32 | -1.19 % | $ 257 M | USA |
 |
AlloVir
ALVR
|
-57.76 | - | 4.14 % | $ 49.1 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
28.05 | $ 25.45 | -1.73 % | $ 1.23 B | USA |
 |
Acasti Pharma
ACST
|
-25.04 | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
-353.66 | - | -15.15 % | $ 60.3 M |  Britain |
 |
Ampio Pharmaceuticals
AMPE
|
-75.24 | - | -11.43 % | $ 502 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-40.28 | - | - | $ 1.01 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | USA |
 |
Ascendis Pharma A/S
ASND
|
-45.89 | $ 210.53 | 0.18 % | $ 5 B |  Danmark |
 |
Albireo Pharma
ALBO
|
-70.32 | - | -0.23 % | $ 916 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
3412.47 | - | - | $ 7.46 M |  Israel |
 |
Alterity Therapeutics Limited
ATHE
|
-104.38 | $ 3.34 | -2.47 % | $ 8.04 B |  Australia |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
AstraZeneca PLC
AZN
|
11.12 | $ 89.68 | -0.68 % | $ 96.9 B | Britain |
 |
Anika Therapeutics
ANIK
|
-41.29 | $ 9.51 | 0.21 % | $ 139 M | USA |
 |
Brickell Biotech
BBI
|
-64.05 | - | -5.38 % | $ 6.06 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-15.33 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
-1339.01 | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-69.03 | - | -7.31 % | $ 87 M | USA |
 |
Aytu BioScience
AYTU
|
-12.81 | $ 2.34 | 2.63 % | $ 14.7 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-92.73 | - | -6.81 % | $ 3.04 B | USA |
 |
Benitec Biopharma
BNTC
|
-10.11 | $ 12.44 | -4.01 % | $ 512 M | USA |
 |
Baudax Bio
BXRX
|
234.36 | - | 0.59 % | $ 63 K | USA |
 |
Avenue Therapeutics
ATXI
|
-403.4 | - | -52.27 % | $ 4.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
15.18 | - | - | - |  Russia |
 |
ChromaDex Corporation
CDXC
|
16.76 | - | -0.88 % | $ 598 M | USA |
 |
Axon Enterprise
AXON
|
2.51 | $ 567.68 | -2.3 % | $ 43 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-115.03 | $ 0.29 | -1.41 % | $ 631 M | Israel |
 |
Catalyst Biosciences
CBIO
|
424.75 | $ 14.52 | -5.16 % | $ 956 M | USA |
 |
Cerus Corporation
CERS
|
-25.34 | $ 2.15 | 0.23 % | $ 397 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
444.94 | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
-75.78 | - | -16.75 % | $ 25.8 M | USA |
 |
Clovis Oncology
CLVS
|
80.97 | - | -7.23 % | $ 13 M | USA |
 |
Biogen
BIIB
|
31.45 | $ 173.83 | 0.77 % | $ 25.3 B | USA |
 |
BioVie
BIVI
|
-95.03 | $ 1.46 | -3.31 % | $ 2.16 M | USA |
 |
Cortexyme
CRTX
|
-40.69 | - | -1.05 % | $ 67.1 M | USA |
 |
Celldex Therapeutics
CLDX
|
-26.11 | $ 27.82 | -0.45 % | $ 1.79 M | USA |
 |
Cellectar Biosciences
CLRB
|
257.01 | $ 3.69 | -2.38 % | $ 45.1 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-60.12 | - | - | $ 2.18 B | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
95.22 | $ 11.44 | - | $ 740 M | USA |
 |
BioNTech SE
BNTX
|
-4.81 | $ 94.72 | -1.33 % | $ 27.2 B |  Germany |
 |
Eloxx Pharmaceuticals
ELOX
|
322.88 | - | -5.68 % | $ 8.28 M | USA |
 |
Acer Therapeutics
ACER
|
146.85 | - | 2.71 % | $ 14 M | USA |
 |
Enochian Biosciences
ENOB
|
903.05 | - | - | $ 40.5 M | USA |
 |
Acorda Therapeutics
ACOR
|
167.74 | - | -24.86 % | $ 820 K | USA |